Clinicopathologic and molecular disease prognostication for papillary thyroid cancer.
Despite its increasing incidence over the last 30 years, the mortality rate of papillary thyroid cancer (PTC) has decreased significantly. Nevertheless, a minority of patients still present with an aggressive form of PTC that can lead to death, even after a prolonged period of survival. Many classifications exist that allow one to stratify the clinical risk of recurrence and death in patients with PTC; however, the parameters upon which they are established are pathological and molecular and, therefore, are revealed only after surgery. The preoperative identification of these aggressive variants of PTC would allow one to schedule a more aggressive operation (e.g., total thyroidectomy together with central and/or mono- or bi-lateral node dissections) in patients with high-risk PTC. This article reviews the parameters used most commonly to differentiate low-risk PTCs from their more aggressive variants and describes some of the newest molecular therapies for this latter group of tumors.
Miccoli
Paolo
P
Department of Surgery, University of Pisa, Via Roma 67, 56126 Pisa, Italy. p.miccoli@dc.med.unipi.it
Miccoli
Mario
M
Antonelli
Alessandro
A
Minuto
Michele N
MN
D000818:Animals; D002291:Carcinoma, Papillary / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D016896:Treatment Outcome